GlobeNewswire·Nov 11, 2026, 7:00 AM ET

Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026

Nkarta Inc. reported integrated safety results for 40 patients treated with NKX019 across five autoimmune indications in the Ntrust program.
No cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), IEC-HS, or graft-versus-host disease (GvHD) were observed.
There were no deaths or treatment discontinuations due to adverse events.
Grade 3 or higher treatment-emergent adverse events were primarily hematologic \& attributed to lymphodepletion.
Five patients (12.5%) experienced infusion-related reactions associated with NKX019, all resolving within 24-48 hours without tocilizumab.
No increase in adverse events was observed at higher doses of 1 billion, 2 billion, or 4 billion cells.
The safety data was presented at the American College of Rheumatology (ACR) Convergence 2026 with a data cutoff of September 18, 2026.
Patients received outpatient lymphodepleting preconditioning followed by a three-dose cycle of the allogeneic NKX019 therapy.
NKX019 is an off-the-shelf product that does not require patient leukapheresis or individualized manufacturing.
The Ntrust trials are evaluating NKX019 in patients with systemic sclerosis, myositis, lupus nephritis, rheumatoid arthritis, \& ANCA-associated vasculitis.